OutsideIn Research - Q&A with Jeff Davis of Access Pharma (OTCBB: ACCP) - Part II
Posted by Mike Sweeney on Wed, Sep 01, 2010 @ 01:42 PM
Jeffrey Davis is the CEO of
Access Pharmaceuticals (OTCBB: ACCP) which is an emerging oncology-focused specialty pharmaceuticals company (January 2008 to present). The OutsideIn Research interview is broken into two sections:
- Part I - covers Access Pharma's strategy and its first product MuGard, which is in product launch now, and
- Part II - covers Access Pharma's three products in the pipeline, Cobalamin, ProLindac, and Thiarabine.
Here is Part II at OutsideIn Research.